Feature

Of ‘miracles’ and money: Why hemophilia drugs are so expensive


 

Sitting at a picnic bench at a park, Jessica Morris pages through Landon’s insurance documents. Over the past year, his care cost over $120,000. She wonders sometimes what would happen if they lost their coverage.

“How much would you be willing to pay to have your child lead a normal life?” she said. “I don’t think that there’s anything we wouldn’t pay or sacrifice for him.”

It’s a problem she prays they’ll never have to face.

Kaiser Health News is a nonprofit news service covering health issues. It is an editorially independent program of the Kaiser Family Foundation that is not affiliated with Kaiser Permanente. KHN’s coverage of prescription drug development, costs, and pricing is supported by the Laura and John Arnold Foundation.

Pages

Recommended Reading

Hemophilia A drug heads toward approval in Europe
MDedge Hematology and Oncology
Gene therapy for hemophilia A gets fast-track review
MDedge Hematology and Oncology
States strive to curb costs for a crucial – but exorbitant – hemophilia treatment
MDedge Hematology and Oncology
Hemophilia A treatment gains approval in Europe
MDedge Hematology and Oncology
PK dosing software available in US
MDedge Hematology and Oncology
EC approves emicizumab for hemophilia A with inhibitors
MDedge Hematology and Oncology
Team creates device to study hemostasis
MDedge Hematology and Oncology
Product seems effective for ITI in severe hemophilia A
MDedge Hematology and Oncology
Product increases FIX levels in hemophilia B
MDedge Hematology and Oncology
Factor IX product launched in US
MDedge Hematology and Oncology